Observational follow up study of MIDAS participants

• Research type

  Research Study

• Full title

  The metabolic impact of Darunavir/Ritonavir maintenance monotherapy after successful viral suppression with standard Atripla in HIV-1-infected patients (MIDAS) – follow on observational study

• IRAS ID

  126608

• Contact name

  Julie Fox

• Contact email

  julie.fox@kcl.ac.uk

• Sponsor organisation

  Guy's & St. Thomas' NHS Foundation Trust

• Research summary

  MIDAS is a 48 week trial to see if switching from Atripla (standard triple HIV drug therapy) to Darunavir/Ritonavir only (single drug therapy) in HIV patients is less toxic for bones and kidneys. At the end of the study, as single drug therapy is not a recommended treatment regime, all participants will be advised to return to standard triple therapy. There is very little data describing what happens when changing from single therapy to triple therapy in HIV. As all MIDAS participants enter routine clinical care, we would like to observe them for a further 48 weeks to see if any changes in kidney and bone are reversed by using a recommended triple therapy regime.

• REC name

  London - Harrow Research Ethics Committee

• REC reference

  13/LO/1125

• Date of REC Opinion

  3 Sep 2013

• REC opinion

  Further Information Favourable Opinion